CCL2/CCR2 Pathway Identified as Key Driver of Aggression in Double-Expressor DLBCL
核心洞察
Researchers have discovered that increased expression of CCL2 (搜索) and CCR2 (搜索) drives aggressive behavior in double-expressor diffuse large B-cell lymphoma (搜索) through enhanced M2 macrophage polarization.
The study revealed significantly elevated CCL2 (搜索) and CCR2 (搜索) mRNA levels in DE-DLBCL (搜索) patients compared to non-DE-DLBCL cases, with high expression correlating with poor survival outcomes.
These findings identify a novel therapeutic target for DE-DLBCL (搜索), potentially offering new treatment strategies for this aggressive form of lymphoma that affects approximately 30% of DLBCL patients.
A groundbreaking study published in Blood Advances has uncovered a crucial mechanism behind the aggressive nature of double-expressor diffuse large B-cell lymphoma (搜索) (DE-DLBCL (搜索)), offering new hope for targeted therapeutic interventions.
Molecular Mechanism of Aggression
Scientists have identified that increased expression of C-C motif chemokine ligand 2 (CCL2 (搜索)) and C-C chemokine receptor type 2 (CCR2 (搜索)) plays a central role in driving the aggressive behavior of DE-DLBCL (搜索). The research revealed that these tumors, characterized by overexpression of both MYC (搜索) and BCL2 (搜索), demonstrate significantly elevated mRNA levels of CCL2 and CCR2 compared to non-DE-DLBCL cases (P adj < .05).
Clinical Impact and Patient Outcomes
The study, which analyzed tumors from 14 DE-DLBCL (搜索) patients and 14 non-DE-DLBCL patients, demonstrated that increased expression of both CCL2 (搜索) and CCR2 (搜索) significantly correlated with poor clinical outcomes. Specifically, high expression levels were associated with reduced progression-free survival (PFS, P = .014) and overall survival (OS, P = .009). The combined high expression of both markers showed similar correlations (PFS: P = .013, OS: P = .017).
Immune Microenvironment Alterations
Detailed analysis revealed that DE-DLBCL (搜索) patients exhibited elevated levels of M2 macrophages but decreased T-cell infiltration in their tumors. The research team found that CCR2 (搜索) expression was predominantly localized to tumor-infiltrating macrophages rather than DLBCL cells themselves. The mechanism involves MYC (搜索) and BCL2 (搜索) increasing CCL2 (搜索) through upregulation of nuclear factor-κB p65, which subsequently promotes M2 macrophage polarization.
Therapeutic Implications
This discovery is particularly significant given the current therapeutic landscape for DLBCL. While existing treatments such as the BCL2 (搜索) inhibitor venetoclax have shown limited efficacy (18% overall response rate), and direct MYC (搜索) targeting has proven challenging, this newly identified CCL2 (搜索)/CCR2 (搜索) axis presents a promising therapeutic target.
The findings are especially relevant for the approximately 30% of DLBCL patients who have double-expressor disease, which currently lacks specific treatment protocols despite its poor prognosis. The research suggests that targeting the CCL2 (搜索)/CCR2 (搜索) pathway could potentially improve outcomes for these patients, particularly in combination with existing chemoimmunotherapy and emerging immunotherapy approaches.
Future Directions
The research team emphasizes that understanding the tumor immune microenvironment and its regulatory mechanisms is crucial for advancing lymphoma treatment. These findings may prove instrumental in developing more effective management strategies for DE-DLBCL (搜索) patients, potentially leading to new therapeutic approaches that could improve survival outcomes for this aggressive form of lymphoma.